Dual-action peptides: A new strategy in the treatment of diabetes-associated neuropathy

Drug Discovery Today

Volumn 11, Issue 5-6, 2006, Pages 254-260

  Tam, Joseph ^a   Diamond, Jack ^b   Maysinger, Dusica ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; C-PEPTIDE; CYTOKINES; DIABETIC NEUROPATHIES; ERYTHROPOIETIN; HUMANS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION;

EID: 33645359730     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03722-0     Document Type: Review

References (81)

1. Boulton A.J. Diabetic neuropathies: a statement by the American Diabetes Association Diabetes Care 28 2005 956 962
2. Dyck P.J. Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy Diabetes Care 28 2005 2192 2200
3. Herman W.H., Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes Diabetes Care 28 2005 1480 1481
4. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N. Engl. J. Med. 329 1993 977 986
5. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKDPS 34) Lancet 352 1998 854 865
6. Kamiya H. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes Ann. Neurol. 56 2004 827 835
7. Ekberg K. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes Diabetes 52 2003 536 541
8. Tam J. INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice FASEB J. 18 2004 1767 1769
9. Vinik A.I., Mehrabyan A. Diabetic neuropathies Med. Clin. North Am. 88 2004 947 999
10. Boulton A.J. Treatment of symptomatic diabetic neuropathy Diabetes Metab. Res. Rev. 19 Suppl 1 2003 S16 S21
11. Rowbotham M.C. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study Pain 110 2004 697 706
12. Westanmo A.D. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor Am. J. Health Syst. Pharm. 62 2005 2481 2490
13. Tomlinson D.R. Neurotrophins and peripheral neuropathy Philos. Trans. R. Soc. Lond. B Biol. Sci. 351 1996 455 462
14. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. 50 2002 393 413
15. Apfel S.C. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group JAMA 284 2000 2215 2221
16. Wellmer A. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy J. Peripher. Nerv. Syst. 6 2001 204 210
17. Huang T.J. Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats Exp. Neurol. 194 2005 279 283
18. Sayers N.M. Neurotrophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats Diabetes 52 2003 2372 2380
19. Middlemas A. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3 Brain 126 2003 1671 1682
20. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies Prog. Brain Res. 146 2004 477 492
21. Kennedy J.M., Zochodne D.W. Impaired peripheral nerve regeneration in diabetes mellitus J. Peripher. Nerv. Syst. 10 2005 144 157
22. Polonsky K.S. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients J. Clin. Invest. 77 1986 98 105
23. Wahren J. Molecular and cellular effects of C-peptide-new perspectives on an old peptide Exp. Diabesity Res. 5 2004 15 23
24. Henriksson M. Separate functional features of proinsulin C-peptide Cell. Mol. Life Sci. 62 2005 1772 1778
25. Zierath J.R. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM Diabetologia 39 1996 1180 1189
26. Grunberger G. Molecular basis for the insulinomimetic effects of C-peptide Diabetologia 44 2001 1247 1257
27. Li Z.G. C-peptide prevents hippocampal apoptosis in type 1 diabetes Int. J. Exp. Diabetes Res. 3 2002 241 245
28. Li Z.G. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells Diabetes Metab. Res. Rev. 19 2003 375 385
29. Ohtomo Y. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y Diabetologia 39 1996 199 205
30. Wallerath T. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide Nitric Oxide 9 2003 95 102
31. Stevens M.J. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats Am. J. Physiol. Endocrinol. Metab. 287 2004 E497 E505
32. Ido Y. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide Science 277 1997 563 566
33. Steiner D.F. The proinsulin C-peptide-a multirole model Exp. Diabesity Res. 5 2004 7 14
34. Henriksson M. Unordered structured of proinsulin C-peptide in aqueous solution and in the presence of lipid vesicles Cell. Mol. Life Sci. 57 2000 337 342
35. Rigler R. Specific binding of proinsulin C-peptide to human cell membranes Proc. Natl. Acad. Sci. U. S. A. 96 1999 13318 13323
36. Marques R.G. C-peptide: much more than a byproduct of insulin biosynthesis Pancreas 29 2004 231 238
37. Brubaker P.L., Drucker D.J. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659
38. Lee S.H. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1 Bioconjug. Chem. 16 2005 377 382
39. Liu H.K. N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression Cell Biol. Int. 28 2004 69 73
40. Kim J.G. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751 759
41. Rafaeloff R. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters J. Clin. Invest. 99 1997 2100 2109
42. Flores L.E. Expression of islet neogenesis-associated protein in islets of normal hamsters J. Endocrinol. 177 2003 243 248
43. Rosenberg L. A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice Ann. Surg. 240 2004 875 884
44. Jamal A.M. Morphogenetic plasticity of adult human pancreatic islets of Langerhans Cell Death Differ. 12 2005 702 712
45. Borelli M.I. INGAP-related pentadecapeptide: Its modulatory effect upon insulin secretion Regul. Pept. 131 2005 97 102
46. Bonner-Weir S., Weir G.C. New sources of pancreatic beta-cells Nat. Biotechnol. 23 2005 857 861
47. Uwaifo G.I., Ratner R.E. Novel pharmacologic agents for type 2 diabetes Endocrinol. Metab. Clin. North Am. 34 2005 155 197
48. Nourparvar A. Novel strategies for the pharmacological management of type 2 diabetes Trends Pharmacol. Sci. 25 2004 86 91
49. Tam J. Islet-neogenesis-associated protein enhances neurite outgrowth from DRG neurons Biochem. Biophys. Res. Commun. 291 2002 649 654
50. Taylor-Fishwick D.A. Cloning genomic INGAP: a Reg-related family member with distinct transcriptional regulation sites Biochim. Biophys. Acta 1638 2003 83 89
51. Kobayashi S. Identification of a receptor for reg (regenerating gene) protein, a pancreatic beta-cell regeneration factor J. Biol. Chem. 275 2000 10723 10726
52. Tam J. Neurite outgrowth in dorsal root ganglia induced by islet neogenesis-associated protein peptide involves protein kinase A activation NeuroReport 17 2006 189 193
53. Liu R.Y., Snider W.D. Different signaling pathways mediate regenerative versus developmental sensory axon growth J. Neurosci. 21 2001 RC164
54. Takatori A. Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments Diabetes Metab. Res. Rev. 20 2004 211 218
55. Gaucher G. Block copolymer micelles: preparation, characterization and application in drug delivery J. Control. Release 109 2005 169 188
56. Nagai A. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture J. Neuropathol. Exp. Neurol. 60 2001 386 392
57. Campana W.M., Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury FASEB J. 15 2001 1804 1806
58. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades Nature 412 2001 641 647
59. Kilic E. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways FASEB J. 19 2005 2026 2028
60. Hoke A., Keswani S.C. Neuroprotection in the PNS: Erythropoietin and Immunophilin Ligands Ann. N. Y. Acad. Sci. 1053 2005 491 501
61. Keswani S.C. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration Ann. Neurol. 56 2004 815 826
62. Bianchi R. Erythropoietin both protects from and reverses experimental diabetic neuropathy Proc. Natl. Acad. Sci. U. S. A. 101 2004 823 828
63. Campana W.M., Myers R.R. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury Eur. J. Neurosci. 18 2003 1497 1506
64. Lipton S.A. Erythropoietin for neurologic protection and diabetic neuropathy N. Engl. J. Med. 350 2004 2516 2517
65. Leist M. Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 2004 239 242
66. Kromminga A., Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview Ann. N. Y. Acad. Sci. 1050 2005 257 265
67. Fischer P.M. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review Curr. Protein Pept. Sci. 4 2003 339 356
68. Doyle M.E. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of like-glucagon peptide-1 produces a long-acting hypoglycemic agent Endocrinology 142 2001 4462 4468
69. Lu W. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery J. Control. Release 107 2005 428 448
70. Moriya H. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats Pharm. Res. 14 1997 1621 1628
71. Saragovi H.U., Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors Trends Pharmacol. Sci. 21 2000 93 98
72. Nielsen L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes Drug Discov. Today 10 2005 703 710
73. Szolcsanyi J. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia Eur. J. Pharmacol. 498 2004 103 109
74. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
75. Tsubery H. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification J. Biol. Chem. 279 2004 38118 38124
76. Zhang W. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats J. Neurol. Sci. 194 2002 21 28
77. Grunberger G., Sima A.A. The C-peptide signaling Exp. Diabesity Res. 5 2004 25 36
78. Kitamura T. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells Biochem. J. 366 2002 737 744
79. Jamal A.M. Signals for death and differentiation: a two-step mechanism for in vitro transformation of adult islets of Langerhans to duct epithelial structures Cell Death Differ. 10 2003 987 996
80. Digicaylioglu M. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I Proc. Natl. Acad. Sci. U. S. A. 101 2004 9855 9860
81. Brines M. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor Proc. Natl. Acad. Sci. U. S. A. 101 2004 14907 14912